HealthCare Konnect and Lucida Medical announce strategic partnership for prostate cancer diagnosis

Healthcare Konnect (HCK) and Lucida Medical partner to extend the distribution of Innovative AI-driven technology, PiTM,
for prostate cancer detection, in Switzerland and Morocco.

Prostate cancer is the second most common cancer in men worldwide, and the number of new cases is expected to double between 2020 and 2040. Early and
accurate detection is crucial in managing the disease and improving patient outcomes. Traditional diagnostic methods can be invasive and may not always accurately identify the presence of cancerous lesions.

In their joint mission to enhance prostate cancer diagnosis, Healthcare Konnect (HCK), a leading distribution platform for innovative healthcare solutions, and Lucida Medical, a pioneer in AI-driven cancer detection technologies, have partnered to offer Lucida Medical’s advanced AI technology, PiTM, in Switzerland and in Morocco. This partnership aims to bring enhanced diagnostic capabilities in local medical facilities.

PiTM, developed by Lucida Medical, is a groundbreaking software platform that automatically analyses MRI scans to identify suspicious lesions. This technology is designed to augment a radiologist’s interpretation of prostate MRI by assisting patient selection/prioritisation for biopsy, helping identify targets for biopsy, and providing high quality visualisation.

“Through our partnership with HCK, we aim to make PiTM accessible to a larger patient population, enabling more accurate and less invasive testing. With AI to combine insights from MRI and clinical data, we seek to transform the experience of men with prostate cancer,” said Dr Antony Rix, CEO of Lucida Medical.

Marwan Senhaji, CEO of HCK says, “We are proud to partner with Lucida Medical to deliver on our mission to scale accuracy in diagnostics. Our medical partners in Switzerland and Morocco are thrilled at the prospect of leveraging the power and efficiency of PI’s software, and greatly improving patients’ outcomes.”

Lucida Medical, established in 2019, specialises in AI-based solutions designed to aid clinicians in the accurate detection, diagnosis, and early treatment of cancer. Lucida Medical brings together some of the foremost experts in AI technology and radiology, from leading clinical institutes across Europe.

Source: press release